Logo

Just Say No

Feb 25, 2009

A special committee of Genentech's board asks the company's investors to reject Roche's hostile bid, reports the Wall Street Journal. Genentech says that the hostile Roche offer, at $86.50 a share, is "inadequate and not in the best interest of shareholders" and undervalues Genentech's financial outlook, its history of developing new medicines, and its product pipeline. Roche responded to the committee's recommendation by saying Roche has made its case and it is now up to the investors.

Breaking News
The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.